Smoothing T cell roads to the tumor: Chemokine post-translational regulation.
We described a novel tumor-associated immunosuppressive mechanism based on post-translational modifications of chemokines by reactive nitrogen species (RNS). To overcome tumor immunosuppressive hindrances, we designed and developed a new drug, AT38, that inhibits RNS generation at the tumor site. Combinatorial approaches with AT38 boost the effectiveness of cancer immunotherapy protocols.
Istituto Oncologico Veneto IRCCS; Padua, Italy.
Barbara
B
Molon
Antonella
A
Viola
Vincenzo
V
Bronte